Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Frederick L. Locke
Advertisement
Dr. Frederick L. Locke serves as chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center and Research Institute, in Tampa, Florida, also explained the mechanism of action of the agent.
Articles by Dr. Frederick L. Locke
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Advertisement
Latest Updated Articles
Breaking Down The Results of The ALPHA/ALPHA2 Study in Large B-Cell LymphomaPublished: March 1st 2025 | Updated:
Advertisement
Advertisement
Trending on CURE
1
Peritoneal Mesothelioma Survivor Shares Ongoing Reality of Survivorship
2
What Does a Stage 2 Prostate Cancer Diagnosis Mean for Me?
3
SUNRiSE-1 Participant Shares Insights on Bladder Cancer Education
4
Becoming Cancer-Aware: How My Diagnosis Changed the Way My Family Sees Everyday Products
5
